CORRIGENDUM

Targeting MET in cancer: rationale and progress

Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier and George Vande Woude

Nature Reviews Cancer **12**, 89–103 (2012)

In the legend to Figure 6c, the distribution according to therapeutic strategy (monotherapy versus combined therapy) involving HGF/SF–MET monotherapies should have read 44%.